Moreover, Balermpas et al. reported that elevated numbers of CD8+ tumor infiltrating lymphocytes (TILs) in SCCHN patients treated with adjuvant RCT serve as a prognostic marker for improved clinical outcome [2]. The gene discussed is CD8A; the disease is head and neck squamous cell carcinoma.